In addition, I note that Regeneus is giving a presentation at a Pharma manufacturer conference in South Korea in April. Could this mean RGS is looking for a another JV/licensing deal, this time in South Korea?
You would think RGS would have confidence in the Progenza STEP trial results to be doing this. We will be finding out soon enough!
(Korean) http://www.kpbma.or.kr/sub/select/00000000034/00000000040/239552
RGS Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
